41:2040059. four. Whiteman DC, Stickley M, Watt P, Hughes MC, Davis MB, Green

41:2040059. 4. Whiteman DC, Stickley M, Watt P, Hughes MC, Davis MB, Green AC: Anatomic internet site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol 2006, 24:3172177. 5. Chaudru V, Chompret A, Bressac-de Paillerets B, Spatz A, Avril MF, Demenais F: Influence of genes, nevi, and sun sensitivity on melanoma danger inside a family sample unselected by loved ones history and in melanoma-prone families. J Natl Cancer Inst 2004, 96:78595. 6. Ferrone CR, Ben Porat L, Panageas KS, Berwick M, Halpern AC, Patel A, Coit DG: Clinicopathological features of and threat variables for numerous main melanomas. JAMA 2005, 294:1647654. 7. Murali R, Goumas C, Kricker A, From L, Busam KJ, Begg CB, Dwyer T, Gruber SB, Kanetsky PA, Orlow I, Rosso S, Thomas NE, Berwick M, Scolyer RA, Armstrong BK, GEM Study Group: Clinicopathologic features of incident and subsequent tumors in patients with multiple main cutaneous melanomas. Ann Surg Oncol 2012, 19:1024033. 8. Bower MR, Scoggins CR, Martin RC 2nd, Mays MP, Edwards MJ, Reintgen DS, Ross MI, Urist MM, Noyes RD, Sussman JJ, Hagendoorn LJ, Stromberg AJ, McMasters K: Second major melanomas: incidence and outcome.Minocycline hydrochloride Am Surg 2010, 76:67581.Fosamprenavir 9.PMID:23935843 De Giorgi V, Rossari S, Papi F, Gori A, Alfaioli B, Grazzini M, Crocetti E, Verdelli A, Foo CW, Lotti T: Various major melanoma: the influence of atypical naevi and adhere to up. Br J Dermatol 2010, 163:1319322. 10. Hwa C, Price LS, Belitskaya-Levy I, Ma MW, Shapiro RL, Berman RS, Kamino H, Darvishian F, Osman I, Stein JA: Single versus multiple key melanomas: old inquiries and new answers. Cancer 2012, 118:4184192. 11. Moscarella E, Rabinovitz H, Puig S, Zalaudek I, Oliviero MC, Brown L, Alarcon I, Malvehy J, Longo C, Formisano D, Carrera C, Badenas C, Piana S, Albertini G, Pellacani G, Argenziano G: Various main melanomas: do they look the same Br J Dermatol 2013, 168:1267272. 12. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199206. 13. Fecher LA, Amaravadi RK, Flaherty KT: The MAPK pathway in melanoma. Curr Opin Oncol 2008, 20:18389. 14. Pritchard AL, Hayward NK: Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance. Clin Cancer Res 2013, 19:2301309. 15. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, et al: Mutations with the BRAF gene in human cancer. Nature 2002, 417:94954.16. Lopez-Bergami P: The function of mitogen- and stress-activated protein kinase pathways in melanoma. Pigment Cell Melanoma Res 2011, 24:90221. 17. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, Hauss J, Wittekind C: Mutation of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003, 52:70612. 18. Colombino M, Sperlongano P, Izzo F, Tatangelo F, Botti G, Lombardi A, Accardo M, Taran-tino L, Sordelli I, Agresti M, Abbruzzese A, Caraglia M, Palmieri G: BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma amongst individuals from South Italy. Cell Death Dis 2012, 3:e259. 19. Greaves.